Nursing Review Issue 4 Jul-Aug 2019 | Page 30

workforce Corporate courtship of nurses When nurses are given financial incentives by big pharma, should we be concerned? Emily Karanges interviewed by Conor Burke N ew data shows pharmaceutical companies are increasingly targeting non-prescribing health professionals, such as nurses, with financial gifts. Payments to doctors by pharmaceutical companies is commonplace and widely accepted, and there is currently no governmental regulation surrounding these types of payments. But this new study raises some ethical issues. The University of Sydney has analysed publicly available data of payments to health professionals, submitted by the pharmaceutical companies and submitted to regulator Medicines Australia. 28 | nursingreview.com.au Looking at the period between October 2015 and April 2018, about 14,000 healthcare professionals received over $62 million in payments from pharmaceutical companies. Of that number, about 18 per cent were nurses. The study’s lead author, Dr Emily Karanges, said: “There is a mistaken idea that non-prescribing healthcare professionals don’t have much influence on medicine use, therefore their pharmaceutical industry ties aren’t that important. Yet healthcare professionals like nurses and pharmacists often assist with medication choice and encourage adherence to treatment – and the roles they play in chronic disease management are expanding too.” Karanges joined Nursing Review to discuss her findings. We saw about 40 per cent attendance by nurses at these events. That’s partly why we wanted to look into this a little more. It’s an overlooked issue. What is the form of these payments? Does anyone get monetary payments? The data encompasses just certain payments. One is sponsored attendance at conferences, where the registration fees are paid. There might be travel and accommodation given as well. So obviously that’s not a physical payment. But there are also payments for fees for service. So, speaking at a conference, participating on an advisory board, or consulting services and the associated travel and accommodation expenses. NR: How did this research come about? Is this practice, for doctors or anyone else, subject to any legal or health department regulations? EK: We have access to pharmaceutical payment data on different healthcare professionals, and we were seeing the number of different health professionals that were coming up in that data. We’d also seen from other data in the past that nurses and other healthcare professionals attend a lot of company- sponsored educational events. Most of the regulation is through the pharmaceutical industry itself. They have a code of conduct that regulates what they’re allowed to do. For example, they can’t fly an Australian to an Australian conference in business class. They can only do it economy. But, they can fly them overseas in business class. They shouldn’t be treating them to a meal over $120.